When Best Practice is Bad Medicine: A new approach to rationing tertiary health services in South Africa by Kenyon, Chris Richard et al.
May 2008, Vol. 98, No. 5  SAMJ
SAMJ FORUM
350
ISSUES IN MEDICINE
When Best Practice is Bad Medicine: A new approach to 
rationing tertiary health services in South Africa
Chris Kenyon, Nathan Ford, Andrew Boulle
South Africa’s democracy inherited a health system biased 
towards tertiary rather than primary health care. Attempts to 
reverse this imbalance in the Western Cape led to rancorous 
response from many sectors. We outline the debate and 
describe the international forces that push developing countries 
into spending excessive amounts on specialised services. 
An alternative way of rationing, utilising cost-effectiveness 
thresholds, is described.
The Western Cape’s Health plan for the future (known as 
‘Healthcare 2010’1) included cutting back tertiary services to 
strengthen primary and secondary levels and to stay within 
budget.  Tertiary hospital staff responded with indignation. A 
crisis committee was set up at Groote Schuur Hospital (GSH) 
and an often acrimonious debate ensued in the press and 
other forums. Bongani Mayosi, Professor of Medicine at GSH, 
explained the basis of the opposition in his submission to the 
Parliamentary Portfolio Committee on Health:2 not only is 
‘health in the Western Cape massively underfunded’, but this 
is ’in the face of rising demand’. Professional staff numbers in 
academic hospitals in the province had decreased by 39% from 
1990 to 2000, and Healthcare 2010 plans to further decrease 
specialists at the province’s three academic hospitals from 
235 to 115 by 2010. The net result would be a deterioration 
in patient care, waiting times and registrar training at these 
facilities. He believes the country’s budget surplus gives us  
‘options for increasing investment in health’. According to Del 
Khan, Professor of Surgery at GSH, the net effect would be that 
GSH ‘will continue to function, but we won’t be producing the 
goods’. The GSH action committee chair, Lydia Cairncross, was 
more critical, stating that cuts to tertiary services exhibited a 
’callous disregard for the lives of the patients entrusted to our 
care and to the care of the administrators of the health system‘, 
her submission to Parliament concluding ‘I will give you one 
simple equation: health cuts equal death and suffering for our 
people’. 
The Democratic Alliance, Treatment Action Committee, and 
Cosatu expressed similar opinions in the press. Cosatu regional 
secretary, Tony Ehrenreich, explained that the cutbacks amount 
to the ‘worst betrayal of provincial government towards the 
poor communities’ and ‘infringe the human rights of people 
who depend on public health care’.
What then was the basis for the 
cutbacks? The case for rationing
One of the reasons for South Africa’s health care system 
being ranked 175th out of 191 countries in the World Health 
Organization (WHO)’s World Health Report 2000 was that we 
get poor value for money from our health system.3 Health 
care expenditure in South Africa is 8.8% of the gross domestic 
product (GDP), compared with a global average of 7.9% and an 
average of 5.1% for other middle-income countries.4 However, 
our health outcomes are very poor and we do very poorly at 
doing the basics properly. Proper treatment of tuberculosis 
and infant vaccination are two of the most cost-effective 
interventions, but South Africa manages a TB cure rate of 
only 59% and vaccination coverage of 1-year-olds of 82%.5 
Socio-economic factors such as sanitation, employment and 
education are primary determinants of a population’s health 
status. Evidence also demonstrates that health systems based 
on strong primary health care (PHC) are more cost effective 
at promoting the health of a population than systems biased 
towards strong secondary and tertiary care.6 By prioritising 
the establishment of good PHC services and dealing with 
social and economic factors, China, Cuba, Costa Rica and Sri 
Lanka had, as of 2004, attained life expectancies of 71 - 78 years 
despite annual health expenditures of US$43 - $290 per capita.7 
South Africa spends $390 per capita, but our life expectancy 
is only 48 years.7 Even before the HIV epidemic our life 
expectancy was 10 - 20 years adrift of these four countries.   
This situation was partly caused by the buildup of 
sophisticated tertiary health care (THC) at the expense of 
decent PHC services. By the end of the apartheid era in 1993, 
acute hospital services consumed 75% of all South Africa’s 
health care expenditure, of which tertiary and academic 
services made up 59%.8  Tertiary services received an even 
larger slice of the cake in the Western Cape, with the net 
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effect of crowding out PHC services. Despite cutbacks to this 
THC sector, and despite spending more on health care than 
any other province apart from Gauteng, the Western Cape 
Department of Health faced a budget deficit, projected to 
reach R1.1 billion by 2010.9 Because treating patients at THC 
as opposed to district level is 2 - 5 times more expensive per 
bed-day,10 Healthcare 2010 aimed to move 1 014 beds from THC 
to district level, and open another 24 level 1 beds and another 
344 level 2 beds. This would cut costs by R502 million and 
increase the total number of acute beds available by 368.9 It was 
conceived as the Western Cape’s way to reorientate health care 
provision to a more PHC-based approach and enhance cost 
effectiveness by ‘balancing health care needs with resources so 
as to produce the greatest common good’.9   
The best practice-affordability tension
What were the forces that led to THC receiving such a 
disproportionate slice of the cake in the apartheid era? Of 
increasing relevance is the contribution played by three factors 
– international global inequalities, drug pricing mechanisms, 
and doctors striving for best practice. These diminish PHC 
expenditure in developing countries as follows: 
1.  The major determinant of the vast differences in health 
expenditure per capita between different countries is their 
respective wealth – measured in units such as GDP per capita.11 
A rich country such as the USA spends $6 096/capita whereas a 
poor country such as Uganda spends only $19/capita.7
2.  Prices of new therapeutic modalities are largely set in 
the developed countries since these countries comprise 80% 
of the pharmaceutical market.l2 Drug prices are determined 
not so much by the investment in their development but by 
how much pharmaceutical companies think that individuals 
and health care providers will pay for them.12 This in turn is 
established by factors such as how effective the new drugs 
are at promoting life and well-being over competitors. For 
example, highly active antiretroviral therapy (HAART), priced 
at US$11 000 per patient per year when released, was accepted 
by most health care providers in developed countries.13 
However this price was unaffordable to most of the world’s 
population, who live on under $2 per day. 
3.  Doctors are legally and ethically obliged to provide the 
best possible diagnostic and therapeutic modalities to each 
patient (the best practice imperative).
The net effect of these factors is demonstrated in Fig. 1, 
where we see the theoretical direction in which the best practice 
doctrine pushed Uganda’s health care system in 2000, when 
HAART first emerged on the market. If Uganda had introduced 
HAART at these prices, it could have consumed 450% of their 
existent total health budget. 
This dynamic continues to play itself out with the 
introduction of new therapeutic or diagnostic modalities. For 
example, ibritumomab tiuxetan is a newly released highly 
effective treatment for non-Hodgkin’s lymphoma, costing  
$24 000 for a single dose. It is not difficult to see how the 
combined effect of the best practice imperative and the 
unaffordability of new similarly priced interventions, unless 
carefully managed, leads to an inevitable spiralling of specialist 
care costs in all countries. High spending on THC is not unique 
to the Western Cape or South Africa. Hospitals in developing 
countries absorb 30 - 50% of total health expenditure, and 
secondary and tertiary hospitals utilise 60 - 80% of this.14
Is there a way to ration THC that will 
protect PHC services?
The WHO and the public health community agree that health 
services must be structured to provide maximum value for 
money.15 That involves favouring more cost-effective activities, 
which is consistent with the ethical view that limited resources 
for health should be allocated to maximise the health benefit 
for the population served. This rationale requires South Africa 
to divert resources to improve highly cost-effective PHC 
services such as curing patients with TB. Cost effectiveness also 
provides a powerful alternative way to ration THC services. 
The predominant form of rationing THC in South Africa has 
been to cut its total allocated budget (largely via imposed staff 
and bed cuts) and not to interfere in the package of services 
offered. This will result in the same package of care simply 
being offered to far fewer patients. An underlying rationale 
for this form of rationing is the perception that specialist-run 
services are inappropriately expensive and unable to ration 
themselves.
An alternative approach would be to decide on an affordable 
package of tertiary care via the application of explicit criteria. 
This would have the advantages of making the rationing 
process more transparent and cost effective and would enable 
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Fig. 1. The genesis of underfunding of PHC in developing countries. How 
international global inequalities (A), drug pricing mechanisms (B) and the 
activities of doctors striving for best practice (C) come together to swamp 
PHC expenditure in developing countries, with the example of the theo-
retical effect of the introduction, in the year 2000, into global markets of 
HAART at $11 000/patient/year on a high HIV prevalence, poor country 
such as Uganda in 2000.
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the benefits of THC to be delivered to a greater proportion of 
the population.
The UK and Australia have structures to evaluate whether or 
not to add new treatments to their national health services. The 
National Institute for Health and Clinical Excellence (NICE) 
in the UK and the Australian Pharmaceutical Benefits Scheme 
(PBS) use different criteria to make these decisions. However, 
both have established de facto cost-effectiveness threshold 
values of around $49 000 per quality-adjusted life-year (QALY), 
which will vary in accordance with the size of the national 
health budget.16,17 Drugs and interventions costing more than 
this are almost inevitably rejected. Since national wealth (GDP/
capita) is the greatest determinant of the size of this health 
budget, the WHO has recommended that the following rough 
thresholds be used when evaluating the  
cost effectiveness of health products:15
•  Highly cost effective: <1 times GDP/capita per disability-
adjusted life-year (DALY) saved (about R20 000 in South 
Africa in 2007)
•  Moderately cost effective: 1 - 3 times GDP/capita per DALY 
saved
• Not cost effective: >3 times GDP/capita per DALY saved.
It might be asking too much of a South African equivalent of 
NICE, at least in the short term, to determine the cost-effective 
packages of care at primary, secondary and tertiary levels. It 
could, however, help us to agree to a set of criteria to evaluate 
new medical technologies. While health planning textbooks 
suggest several criteria that should be used in this evaluation 
process, one of these should be a cost-effectiveness threshold.
The utility of this approach is illustrated by a decision by the 
Groote Schuur Hospital Medicine Meeting to motivate to the 
Therapeutics Committee for the procurement of rivastigmine 
for the treatment of Alzheimer’s dementia. The treatment 
would cost R12 000 per year for moderately slowing the 
rate of decline of the dementing process. None opposed the 
motion, as we have no nationally agreed frame of reference 
with which to decide if this is too expensive. What would the 
benchmark be of a claim that this was not cost effective? Of 
interest, NICE has just re-evaluated its recommendations on 
rivastigmine. Whereas before it was deemed cost effective for 
mild and moderate Alzheimer’s, it is now regarded as cost 
effective for moderate disease only. Given the 10 times greater 
health expenditure per capita in the UK, it is very unlikely that 
rivastigmine would be deemed cost effective in South Africa at 
current prices.
Apportioning blame in proportion 
to responsibility in an age of global 
apartheid 
The introduction of HAART at $11 000 represented the first 
time that a whole class of highly efficacious medications would 
be completely unaffordable to the majority of those afflicted by 
a mass condition. If the public health community had merely 
accepted these high prices, then HAART would certainly have 
remained unaffordable for the many high-prevalence and poor 
countries. A key part of rationing in the new era is therefore 
exposing the unfair pricing system and campaigning for 
alternative systems. So far this pressure has yielded a crucial 
amendment to the Trade Related Intellectual Property Rights 
System. This enables countries such as South Africa to import 
or manufacture cheap generic antiretrovirals at one-hundredth 
of the initial price of HAART.13 Cost-effectiveness thresholds 
can assist in this process. If a new life-saving medication, such 
as HAART, is introduced at a price that is 37 times the GDP/
capita of a country like Uganda, and generic production could 
produce the medication for 30% of its GDP/capita, then the 
ethical conclusions to be drawn are clear. It is not the fault of 
the Ugandan state that it cannot afford the new treatment, but 
rather the international forces which allow the pharmaceutical 
industry to get away with these pricing strategies. This 
suggests that if a new efficacious treatment is introduced at 
more than 1 - 3 times the GDP/capita of the poorest country 
affected by the illness, then there is a moral imperative to find 
ways to bring down the prices for this country.  (A similar logic 
applies to the pricing and provision of chronic medications. 
If the standard medical treatment of ischaemic heart disease, 
using the cheapest available beta-blocker, ACE inhibitor, statin 
and aspirin, in a country such as Malawi costs the equivalent 
of 18 days’ wages of the lowest paid civil servant, then clearly 
such treatment should be regarded as overpriced.18)  
Seen in this light, the role of doctors is therefore to fight for 
all efficacious treatments to be available for all our patients, 
but to do so keeping sight of the bigger picture. Only if drugs 
are priced affordably should we be placing pressure on our 
national providers for their inclusion. If they are not, then we 
need to lobby at multiple (mostly international) levels to ensure 
that prices are lowered so that all our patients receive treatment 
on the basis of need rather than wealth.
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Inadequate infection prevention and control (IPC) practices 
have highlighted concerns about the medical transmission 
of blood-borne and air-borne pathogens in South Africa. The 
National Department of Health (NDOH) and its partners have 
renewed efforts to minimise the risk of health care-associated 
transmissions.  The success of this endeavour depends on the 
involvement and dedication of doctors, nurses and all those 
who handle health risk waste. 
A key partner, Making Medical Injections Safer (MMIS), has 
implemented their project in 11 countries, including South 
Africa, since 2004.  The project is funded by the US President’s 
Emergency Plan for AIDS Relief (PEPFAR) and managed 
by John Snow, Inc. and its subcontractors, the Program 
for Appropriate Technology in Health, the Academy for 
Educational Development and the Manoff Group. 
The project promotes interventions aimed at preventing 
the transmission of health care-acquired infections and other 
blood-borne illnesses like HIV and AIDS by improving 
injection safety practices. These include safe management of 
sharps waste and promoting the rational use of injections. 
The project supports the strategies of the Safe Injection Global 
Network and the World Health Organization ensuring: the 
availability of appropriate injection-related commodities in 
medical settings; behaviour change and communications 
including training; to support the administration of safe 
and necessary injections; and appropriate health care waste 
management.  
MMIS supports Government efforts through the 
Departments (or Ministries) of Health and Environment, 
helping to implement a range of activities. These include the 
development and/or review of policies, the development 
of norms and standards, the introduction of their use, and 
monitoring their maintenance. The Departments or Ministries 
of Health also guide the implementation of training and 
behaviour change and communication activities, either for 
injection safety as a stand-alone programme area or, as in South 
Africa, within the context of IPC. Such activities have led to the 
development of the country’s first training manual on injection 
safety and the production of print, video, and computer-based 
educational materials for health care personnel. This training 
content is structured for different audiences, including top and 
middle managers of health care facilities, clinical staff, general 
assistants and waste handlers.  
The country has seen an increase in infant deaths associated 
with poor injection equipment use and practices, leading 
to outbreaks of Klebsiella as well as anecdotal reports of 
medical transmission of HIV.  These incidents have influenced 
the public and policy makers on IPC and overall safety, 
particularly in public health hospitals. 
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